China Pharma Holdings Inc
China Pharma Holdings Inc is a company principally engaged in the development, manufacture and marketing of pharmaceutical products. The Company's products are for human use in connection, and with a variety of high-incidence and high-mortality diseases and medical conditions prevalent. The Company manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. In addition, the Company is also engaged in the production of comprehensive healthcare products and protective products.
Stock Performance Snapshot
Financial Health
China Pharma Holdings Inc has modest revenue and cash flow, indicating stable but limited financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring CPHI
Supply Chain Reshoring Investment Theme Explained
In response to Chinese export controls, the US announced a 100% tariff on all Chinese imports, escalating the trade war. This creates a potential investment opportunity in American companies poised to benefit from the reshoring of manufacturing and supply chains.
Published: October 11, 2025
Explore BasketU.S.-China Trade Truce | Investment Opportunities
High-level talks between the U.S. and China are underway to prevent the return of tariffs, a critical step for global economic stability. This creates a potential investment opportunity in companies poised to benefit from improved trade relations and the removal of trade barriers.
Published: September 15, 2025
Explore BasketChina's Biopharma Innovators: The Next Global Partnership Wave
Following GSK's major licensing deal with China's Jiangsu Hengrui, a new investment theme is emerging around Chinese pharmaceutical innovators. This theme focuses on other Chinese biopharma companies that are likely to attract similar global partnerships, driving value through their advanced drug development pipelines.
Published: July 28, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Micro-cap market dynamics
Low market capitalisation often leads to pronounced price swings and limited liquidity; investors should be prepared for higher volatility.
China exposure factors
Regulatory, currency and reporting environments in China can materially affect performance, so review cross-border risks and disclosures carefully.
Sector specifics to watch
Pipeline updates, approvals or partnerships can move the share price significantly, though outcomes are uncertain and subject to regulatory review.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
